trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

The ERASE LC trial, an open-label feasibility study of remdesivir in people with long COVID, has reported results.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 2 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that the ERASE LC trial, an open-label feasibility study of remdesivir in people with long COVID, has reported results?

Yes. Three items (a peer-reviewed abstract, a preprint, and a duplicate record) present results from the ERASE LC open-label feasibility trial of intravenous remdesivir in long COVID, reporting enrollment, treatment completion and adverse events. Three other records describe the same study as planned or ongoing, without results.

Verdict: SUPPORTED · 3 sources for, 2 against · Last checked

The private library was unavailable for some searches in this check. Missing library results are not evidence against the claim.

Evidence for · 3
An Open-Label Feasibility Study of Remdesivir in Long COVID: Results from the ERASE LC Trial
2026
Get citation
Faghy, M. A., Chynoweth, J., Barnett, A., Skipper, L., Allgar, V., Neilens, H., Sands, K., Lord, A., Hambly, H., Aspinall, P. J., Rollinson, C., Strain, W. D., Owen, R., Thomas, C., Grigg, M. J., Kranen, S. H., Mokbel, K., Knapp, K. M., Razak, H. A., & Ashton, R. (2026). An Open-Label Feasibility Study of Remdesivir in Long COVID: Results from the ERASE LC Trial. doi.org. https://doi.org/10.1093/oxfimm/iqag014

Evidence against · 2
An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
2024
Get citation
An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.. (2024). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05911906

See more details
More for · 2
An Open-Label Feasibility Study of Remdesivir in Long COVID: Results from the ERASE LC Trial
2026
Get citation
MA, F., J, C., A, B., L, S., V, A., H, N., K, S., A, L., H, H., PJ, A., C, R., WD, S., R, O., C, T., MJ, G., SH, K., K, M., KM, K., HA, R., & R, A. (2026). An Open-Label Feasibility Study of Remdesivir in Long COVID: Results from the ERASE LC Trial. doi.org. https://doi.org/10.64898/2026.07.26.26358852

An Open-Label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long COVID – ERASE LC
2026
Get citation
Faghy, M. A., Chynoweth, J., Barnett, A., Skipper, L., Allgar, V., Neilens, H., Sands, K., Lord, A., Hambly, H., Aspinall, P. J., Rollinson, C., Strain, D., Owen, R., Thomas, C., Grigg, M. J., Kranen, S. H., Mokbel, K., Knapp, K., Razak, H. A., & Ashton, R. (2026). An Open-Label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long COVID – ERASE LC. doi.org. https://doi.org/10.2139/ssrn.6392486

More against · 1
An open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID
2026
Get citation
Neilens, H., Allgar, V., Sands, K., Chynoweth, J., Lord, A., Aspinall, P. J., Hambly, H., Barnett, A., Skipper, L., Bewick, T., Maidment, I., Razak, H. A., Ashton, R., Strain, D., Knapp, K., & Faghy, M. A. (2026). An open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID. doi.org. https://doi.org/10.21203/rs.3.rs-9019936/v1

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work